Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.46 |
| ▸ | PDE9A | O76083 | 7/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.39 |
| ▸ | PDE1A | P54750 | 4/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681397 | 0.83 | PIK3CA (0.39) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1680101 | 0.73 | LMNA (0.36) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1359010 | 0.72 | PIK3CB (0.59) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL21980548 | 0.71 | MTOR (0.42) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1680093 | 0.70 | PIK3CA (0.41) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1680103 | 0.69 | FLT3 (0.40) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1359008 | 0.69 | MTOR (0.49) | MTORPDE9APDE1CPIK3CAPIK3CD | |
| SCHEMBL1680396 | 0.69 | PIK3CB (0.61) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1680089 | 0.68 | PIK3CA (0.40) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Hydrochloric Acid SCHEMBL11898611 | 0.68 | MTOR (0.48) | MTORPDE9APIK3CAPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | claimed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | MTOR 38/4885PDE9A 740/4885PDE1C 709/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | MTOR 2086/4885PDE9A 1292/4885PDE1C 2524/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | MTOR 2086/4885PDE9A 1292/4885PDE1C 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.